Seminars in Hematology
Volume 44 , Page S1 , July 2007

Introduction: Treatment of Patients With Rituximab-Refractory Indolent Non-Hodgkin’s Lymphoma

  • Stephanie A. Gregory (Guest Editor)

      Affiliations

    • Corresponding Author InformationAddress correspondence to Stephanie A. Gregory, MD, The Elodia Kehm Professor of Medicine, Director, Section of Hematology, Rush University Medical Center/Rush University, 1725 W Harrison St, Suite 834, Chicago, IL 60612-3828.

References 

  1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475
  2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol. 1993;20:75–88
  3. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–1459
  4. Friedberg JW, Huang J, Dillon H, et al. Initial therpeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol. 2006;24:428s;(abstr 7527)
  5. Colombat P, Brousse N, Morschhauser F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analyses with extended follow-up (F/Up) of 7 years. Blood. 2006;108:147a;(abstr 486)
  6. Balfour JA, Goa KL. Bendamustine. Drugs. 2001;61:631–638

PII: S0037-1963(07)00097-2

doi: 10.1053/j.seminhematol.2007.06.006

Seminars in Hematology
Volume 44 , Page S1 , July 2007

Article Tools